Targeted Chemo Offers Hope for Pancreatic Cancer

A new targeted chemotherapy delivery system, Trans-Arterial Micro-Perfusion (TAMP), is offering renewed hope for patients with locally advanced pancreatic cancer. This innovative approach, developed by RenovoRx, aims to send chemotherapy drugs directly to the tumor site via a catheter, rather than circulating them throughout the body. This method significantly reduces the harsh side effects associated with traditional chemotherapy, such as nausea and exhaustion.

Hernando Salcedo, an 83-year-old patient, experienced remarkable improvements after enrolling in a Phase III clinical trial. He reported a significant increase in appetite and energy levels, feeling much better than with conventional chemotherapy. Initial data from the TIGeR-PaC trial suggest that TAMP may lead to improved overall survival and progression-free survival, with substantially fewer adverse events compared to standard IV chemotherapy.

The TAMP platform utilizes the FDA-cleared RenovoCath device. Doctors inflate small balloons on the catheter to isolate an arterial segment near the tumor, then infuse chemotherapy. This precise delivery bathes the tumor directly, minimizing exposure to healthy tissues. Experts highlight that less than 10% of IV chemotherapy reaches pancreatic tumor cells due to physical barriers, making targeted delivery a critical advancement.

RenovoRx expects to complete enrollment in its Phase III trial by mid-2026, with final results anticipated in 2027. If successful, these findings could support a new drug application for intra-arterial gemcitabine. The company also sees potential for this platform in treating other solid tumors, expanding treatment options for patients with limited choices.